Press Release: Cardialen : Cardialen Receives FDA Approval to Conduct Clinical Trial of Low-Energy Atrial Fibrillation Treatment

MINNEAPOLIS--(BUSINESS WIRE)-- #Cardialen--Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a clinical trial of its MultiPulse Therapy (MPT ) to treat paroxysmal and persistent atrial fibrillation (AF). MPT is delivered as a sequence of low-energy electrical pulses designed to restore abnormally rapid heart rates, such as AF, to a normal rhythm in a manner potentially less painful to the patient. This FDA-approved